EADV Congress 2026 · Abstract AS-4094 · e-Poster P1290

Biocompatibility and Collagen Gene Upregulation by a Novel Topical Cannabidiol Formulation in Ex Vivo Human Skin

Marnie Peterson, Tobias Ripsom, Isabel Laubach

Perfectus Biomed/NAMSA (Jackson, WY) · GALYNA.co (Denver) · University of California Davis

Download e-Poster (PDF) Download e-Poster (PPT)
Preview of e-Poster P1290. Title: Biocompatibility and Collagen Gene Upregulation by a Novel Topical Cannabidiol Formulation in Ex Vivo Human Skin

Page 1 of the e-Poster

At a glance

24 / 48 / 72 h

Ex vivo human skin explants

≥88%

Biocompatible up to 72 h (MTT assay). A1 and A2 viability vs saline

COL1A1

Gene expression increased at 24, 48 and 72 h (RT-qPCR)

n = 2 to 3

Biological replicates per condition

About this study

This two-phase study evaluated a novel topical composition of cannabidiol and lipid (CBD test composition, A1) and its vehicle base (A2) on ex vivo human skin explants, measuring biocompatibility by MTT assay and COL1A1 gene expression by RT-qPCR at 24, 48 and 72 h. A1 was biocompatible up to 72 h and COL1A1 expression increased at all three timepoints, while the vehicle base produced a smaller response that was not sustained, consistent with a cannabidiol-dependent effect. The authors describe these findings as exploratory and hypothesis-generating.

Interpretation & limitations

  • Findings come from an ex vivo explant model with small replicate numbers (n = 2 to 3).

  • They are hypothesis-generating and have not yet been confirmed in vivo or clinically.

  • The differences between A1 and A2 at 72 h support a CBD-dependent effect, but the mechanism has not been tested.

  • Ex vivo skin viability above 100% for the CBD test composition (A1) is an MTT metabolic-activity readout relative to saline controls, not a validated proliferation assay.

Contact

Marnie Peterson

PharmD, PhD

Funding & disclosure

This work was conducted by Perfectus Biomed/NAMSA and sponsored by GALYNA.co (TF Holdings LLC). Dr. Marnie Peterson and Tobias Ripsom are affiliated with GALYNA and authors on this abstract. This relationship is disclosed per EADV policy.

Research presented for scientific exchange. Findings are preliminary and not a claim about any product's performance in people.

© 2026 GALYNA® · galyna.co